Lexicon Pharmaceuticals, Inc. (LXRX) Set to Announce Quarterly Earnings on Wednesday
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is scheduled to announce its earnings results before the market opens on Wednesday, November 8th. Analysts expect the company to announce earnings of ($0.36) per share for the quarter.
Lexicon Pharmaceuticals, Inc. (NASDAQ LXRX) traded up $0.02 during trading hours on Monday, hitting $10.01. 130,921 shares of the stock traded hands, compared to its average volume of 688,770. Lexicon Pharmaceuticals, Inc. has a one year low of $9.88 and a one year high of $18.00. The company has a current ratio of 1.86, a quick ratio of 1.85 and a debt-to-equity ratio of 0.80.
COPYRIGHT VIOLATION WARNING: This news story was first reported by Watch List News and is owned by of Watch List News. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of international copyright & trademark laws. The correct version of this news story can be viewed at https://www.watchlistnews.com/lexicon-pharmaceuticals-inc-lxrx-set-to-announce-quarterly-earnings-on-wednesday/1682993.html.
Several research firms have recently commented on LXRX. Wedbush restated an “outperform” rating on shares of Lexicon Pharmaceuticals in a report on Thursday, October 5th. Needham & Company LLC reaffirmed a “buy” rating and issued a $21.00 price objective on shares of Lexicon Pharmaceuticals in a research note on Sunday, September 17th. Cowen and Company reaffirmed a “hold” rating on shares of Lexicon Pharmaceuticals in a research note on Tuesday, August 1st. BidaskClub lowered shares of Lexicon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday, August 10th. Finally, Zacks Investment Research lowered shares of Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 17th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $28.75.
In related news, insider Lonnel Coats acquired 30,000 shares of the business’s stock in a transaction dated Friday, September 15th. The stock was acquired at an average price of $12.54 per share, with a total value of $376,200.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 5.77% of the stock is currently owned by corporate insiders.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.
Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.